New research reveals that intermittent fasting can significantly enhance the effectiveness of oestrogen-blocking breast ...
Among more than 4,000 patients with hormone receptor (HR)-positive disease, 3-year invasive disease-free survival (IDFS) ...
Giredestrant significantly improved IDFS in ER-positive, HER2-negative early breast cancer, reducing recurrence or death risk by 30% compared to SOC endocrine therapy. Subgroup analyses showed ...
Aromatase inhibitors demonstrated superior disease-free survival and time to distant recurrence compared to SERMs in HR+/HER2+ early breast cancer. The benefits of aromatase inhibitors were consistent ...
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ...
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant ...
In premenopausal women with non-metastatic breast cancer, use of tamoxifen may nearly double the risk of endometrial cancer, researchers report.
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ...
Researchers at the University of Gothenburg can now demonstrate previously unexplained processes behind growth therapy. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback